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Background: The purpose of this study was to validate high-frequency ultrasound (HFU) measurement of dermal
thickness for quantification of edema in patients with different severities of chronic venous disease.
Methods: HFU measurements of dermal thickness were made with a 17-MHz probe (Philips iU22 Ultrasound scanner,
Bothell, Wash) or a 20-MHz medium-focus probe (DermaScan-C, Cortex Technology, Denmark), 7.5 cm above the medial
malleolus. For validation, 20 patients with venous leg ulcers who were not receiving compression therapy, 20 patients with
previous deep vein thrombosis (DVT) and symptoms of post-thrombotic syndrome (PTS) without ulceration, and 31
age-matchedhealthy controlsweremeasured on a single occasion.To investigate the effect of compression ondermal thickness,
the leg ulcer patients from the validation study were treated with compression therapy for 7 weeks and measured after 1, 3, 5,
and 7 weeks. The association between dermal thickness and the clinical (C) component of the CEAP classification was
examined in a cross-sectional analysis of 157 patients with a confirmed history of DVT >3 years ago.
Results:Dermal thickness in patientswith venous leg ulcers before compression therapy (median, 2.56mm; interquartile range
[IQR], 2.31-2.82 mm) was significantly greater (P  .002) than that in patients with symptoms of PTS without ulceration
(median, 2.16 mm; IQR, 1.90-2.36 mm). Dermal thickness in both groups was significantly greater (P < .0001) than the
control group (median, 1.34 mm; IQR, 1.29-1.44 mm). Compression therapy caused a steady and significant decrease in
dermal thickness during the first 5weeks until normal control levels were achieved. Dermal thickness increasedwith increasing
CEAP category. In 121 patients with a positive diagnosis of DVT >3 years ago from Radiology Department records, a
hypothetical test cutoff of 1.985 mm for the prediction of severe PTS noted as C4b, C5, and C6 (lipodermatosclerosis or leg
ulceration) had a positive predictive value of 46.9% and a negative predictive value of 90.3%.
Conclusion:HFU measurement of dermal thickness enables the monitoring of edema reduction by compression therapy.
A prospective study is required to determine the temporal dynamics of dermal thickness changes after DVT and the
relationship to the development of PTS. This test has the potential to be beneficial in the follow-up of patients after a
DVT and provide clinical evidence for using graduated elastic compression stockings to control edema and prevent the
development of more advanced skin changes. ( J Vasc Surg 2009;50:820-5.)Objective methods for early detection of skin changes
in chronic venous disease are not readily available; similarly,
means for assessing the effect of compression therapy are
limited. Assessment is frequently based on the gross appear-
ance of subjective skin changes, such as edema, pigmenta-
tion, and induration, and in the case of venous ulceration,
monitoring changes in ulcer size.
In patients with venous insufficiency, increased venous
pressure is transmitted to the capillary bed, increasing hy-
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820postatic pressure and predisposing to edema.1 Edema is
frequently the first clinical sign of venous insufficiency but
may be hard to detect visually or by palpation in the early
stages. The severity of edema, from slight to very marked, is
often reported on a subjective 4-point scale.2 Existing
methods of edema quantification in venous disease such as
leg circumference measurements and leg volume method
for measurement of edema are insensitive, and only relative
changes can be determined. A sensitive, quantitative mea-
sure of edema would be a valuable tool to assess the early
development of skin changes in patients who have had a
previous deep vein thrombosis (DVT) or to assess the effect
of compression therapy.
High-frequency ultrasound (HFU) imaging provides a
noninvasive means to quantify edema, because edema pro-
duces an increase in dermal thickness3 and HFU produces
high-resolution images of the dermis that allow accurate
measurements.4-7 A previous study used dermal thickness
assessed by HFU to quantify edema in venous leg ulcer-
ation.8 Other studies have shown a relationship between
dermal echogenicity and chronic venous disease,9-11 but
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difficult to calculate than the relatively simple measurement
of dermal thickness.
The purpose of this study was to validate HFU mea-
surement of dermal thickness as a tool to quantify edema in
patients with different severities of chronic venous disease;
specifically, patients with chronic venous leg ulcers, patients
with other symptoms of post-thrombotic syndrome (PTS),
and healthy controls. Two potential clinical applications of
the technique were then investigated: (1) The effect of
compression therapy on dermal thickness in patients with
chronic venous leg ulcers, and (2) the relationship between
dermal thickness and the clinical (C) component of the
CEAP classification of venous disease in patients with a
history of DVT.
MATERIALS AND METHODS
This study was approved by the South Metropolitan
Area Health Service Human Research Ethics Committee.
All individuals who participated in this study were recruited
at Fremantle Hospital, and all participants provided written
informed consent.
Three separate studies were performed to evaluate der-
mal thickness as a tool for the assessment of chronic venous
disease. These consisted of:
1. a validation study to compare dermal thickness in
healthy individuals and in those with chronic venous
disease,
2. a compression therapy study to assess the effect of
compression therapy on dermal thickness in individuals
with chronic venous disease, and
3. a study to compare the dermal thickness in patients with
different levels of chronic venous disease using the clin-
ical component of the CEAP classification.
Validation study. This study assessed three groups:
patients with chronic venous ulcers, patients with signs of
PTS but without ulceration, and control participants.
The chronic venous ulcer group comprised 20 patients
with an ulcer on the leg in the gaiter region, with confir-
mation of chronic venous disease by photoplethysmogra-
phy (venous refilling time 25 seconds) and exclusion of
arterial disease by Doppler ankle-brachial index (ABI)
0.8. This group is C6 on the CEAP classification.
The PTS group comprised 20 patients with a history of
DVT of the leg 3 years previously, confirmed by DU
venous scanning or venography, and one or more of the
following symptoms: lower limb edema, hyperpigmenta-
tion, venous eczema, or lipodermatosclerosis. Individuals
were excluded from this group if they had a history of leg
ulceration. This group was C3, C4a, and C4b on the CEAP
classification.
The control group of 31 individuals, with a similar age
distribution to the PTS and venous ulcer groups, was
recruited from employees and volunteers at Fremantle
Hospital. These individuals had no clinical evidence of
varicose veins or telangiectases, no history of DVT or
chronic venous leg ulceration, and no evidence of venousdisease on photoplethysmography (venous refilling time
25 seconds). Arterial disease was excluded (Doppler
ABI 0.8).
Individuals with a medical history of diabetes, rheuma-
toid arthritis, and renal or cardiac problems were excluded
from all groups.
Compression therapy study. After the validation
study, the 20 patients with venous leg ulcers were entered
into the compression therapy study. The dermal thickness
was measured, and then these patients commenced com-
pression therapy for the treatment of their venous ulcer. A
simple nonadherent dressing was applied to the wound,
and the compression therapy consisted of a layer of padding
with orthopedic wool (Velband; Smith & Nephew, Hull,
United Kingdom), two inelastic compression bandages
(Comprilan, Smith & Nephew), and a retention layer of
elasticized tubular bandage (Tubigrip, ConvaTec, Victoria,
New South Wales, Australia). Bandages and primary dress-
ings were changed two to three times weekly, depending on
the amount of exudate. The dermal thickness was remea-
sured after 1, 3, 5, and 7 weeks of compression therapy.
CEAP classification study. A total of 157 individuals
were entered into the study, comprising 121 patients with a
history of DVT 3 years previously, confirmed by duplex
venous scan or venography, who were identified through
the Fremantle Hospital Radiology Department database,
and 36 with DVT and venous ulceration who were identi-
fied through the Fremantle Hospital Vascular Research
Laboratory. Patients were invited to attend a study visit at
which the CEAP classification was determined by clinical
examination.12 The study excluded individuals who were
unable to attend a study visit or who had malignant disease.
Scanning protocol. HFU imaging was performed
with using a 17-MHz linear probe on a B-mode diagnostic
ultrasound scanner (Phillips iU22, Bothell, Wash) or with a
20-MHz medium-focus probe on a portable B-mode scan-
ner (DermaScan C, Cortex Technology, Denmark).
TheHFU assessment of the leg was performed with the
patient in a side position. Three independent transverse
measurements were taken at 7.5 cm above the medial
malleolus, and the mean of the three measurements was
used in subsequent analysis. Dermal thickness was mea-
sured between the surface of the epidermis and the interface
of the dermis with the subcutaneous tissue layer. Measure-
ments with the Phillips iU22 scanner consisted of the
dermal thickness at a single point (Fig 1). Measurements
with the DermaScan-C consisted of the mean of 224 A-
mode scans along a 12.1-mm continuous scanning length
(Fig 2).
Statistical analysis. Nonparametric statistics were
used to analyze the data due to the nonsymmetric distribu-
tion of dermal thickness in the group with venous leg
ulcers. Pair-wise comparisons of dermal thickness between
the three groups in the validation study (venous leg ulcer,
PTS, and healthy controls) were tested for significance
using a two-sided Mann-WhitneyU test. For individuals in
the compression therapy study, pair-wise comparisons of
dermal thickness between compression treatment time
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Wilcoxon signed rank test for paired samples.
In the CEAP classification study, two stages of analysis
took place. First, dermal thickness levels were compared
among the CEAP categories using the Jonckheere-Terpstra
test for a priori ordered categories.13 Second, pair-wise
comparisons of dermal thickness between categories C0,
C1, C2, and C3 and the healthy controls from the validation
study were tested for significance using a two-sided Mann-
Whitney U test.
To test whether gender and type of scanner were sig-
nificant sources of variation, regression analysis was per-
formed using the R statistical package (R Foundation for
Statistical Computing, Vienna, Austria).14 Gender and dis-
ease group were fitted as factor variables in the validation
study, and CEAP category and scanner were fitted as factor
variables in the CEAP classification study.
To determine the appropriate cutoff value of dermal
thickness for a test for severe post-thrombotic outcomes
(C4b) based on data from the CEAP classification study,
receiver-operating characteristic (ROC) curve analysis was
performed using SPSS 17.0 software (SPSS Inc, Chicago,
Ill). The ROC curve is a representation of the trade-off
between sensitivity and specificity, and the area under the
curve (AUC) is a measure of the test’s discriminatory power
(0.5  chance response; 1.0  perfect test).15 The level of
significance for all statistical tests was P .05. The Bonfer-
roni correction was applied when multiple pair-wise tests
were performed.
RESULTS
All significant results presented were significant after
the Bonferroni correction was applied.
Validation study. Table I summarizes the demo-
graphics of individuals in the validation study. As expected
because of age-matching, the difference in age between the
three groups was not statistically significant. The control
Fig 1. Image of dermal thickness measurement obtained using
the Phillips iU22 scanner.group contained a higher proportion of women than theother two groups, and gender was examined as a potential
source of variation. When disease group and gender were
fitted as factor variables in regression analysis, the effect of
gender on dermal thickness was small (estimated effect size,
0.017 mm) and not significant (P  .07).
The median dermal thickness in the control group was
1.34 mm (interquartile range [IQR], 1.30-1.44 mm). The
PTS group without ulceration showed significantly in-
creased dermal thickness compared with the controls (P 
.0001), with a median of 2.16 mm (IQR, 1.90-2.36 mm).
Dermal thickness in patients with venous leg ulcers was
2.56 mm (IQR, 2.31-2.82 mm), which was significantly
higher than healthy skin (P  .0001) and also significantly
higher than the PTS group without ulceration (P  .002;
Fig 3).
Compression study. These patients were the venous
ulcer group whose demographics are summarized in Table
I. After 1 week of compression bandaging, the dermal
thickness in the venous ulcer group (median, 2.56 mm;
IQR, 2.31-2.83 mm) reduced significantly (P  .0002;
median, 1.82 mm; IQR, 1.64-2.14 mm; Fig 4). Dermal
thickness continued to decrease significantly from week 1
to week 3 (P  .0004) and from week 3 to week 5 (P 
0.002), at which point dermal thickness (median, 1.39
mm; IQR, 1.23-1.45 mm) was similar to the normal con-
trol levels in the validation study.
CEAP classification study. All CEAP groups con-
tained participants who were measured by the two scan-
ners. When CEAP classification and scanner were fitted as
factor variables in regression analysis, the effect of scanner
was not significant (P .10).
Table II summarizes the CEAP classification profile
and demographics of participants in the CEAP classification
study. There was an increasing trend in dermal thickness
with increasing CEAP category (Fig 5), and this increase
was highly significant using the Jonckheere-Terpstra test
for ordered categories (P  .0001). When categories C0,
C1, C2, and C3 were compared, pair-wise with the healthy
controls from the validation study (no history of DVT), C2
and C3 were each significantly different from healthy controls
(P .0008 and P .0002, respectively), but not C0 or C1.
To test the clinical utility of a test based on dermal
thickness to predict patients with severe post-thrombotic
outcomes documented as C4b-6(lipodermatosclerosis, healed
or active leg ulcers), we used ROC curves to analyze the
data from the 121 patients with a positive diagnosis of DVT
3 years ago from Radiology Department records. These
patients were a subgroup of the 157 patients in the CEAP
classification study. We assumed that the increase in dermal
thickness occurs as a result of the DVT and pre-dates the
development of skin changes. A ROC curve constructed
from the dermal thickness measurements was significant (P
.0001) for the prediction of severe post-thrombotic out-
comes (C4b), with an AUC of 0.751 (95% confidence
interval [CI], 0.655-0.848), which indicates a test of fair
clinical utility. The optimal cutoff value of 1.985 mm was
selected as that which gave the highest sensitivity (sensitiv-
ity, 76.7%; 95% CI, 57.3%-89.4%), with a specificity of
ment
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patients with a dermal thickness 1.985 mm by positive
test result, 46.9% (95% CI, 32.8%-61.6%) had clinical evi-
dence of severe PTS, resulting in a positive predictive value
of 46.9%. Of the 75 of patients who had a negative test
result, 9.7% had severe PTS, for a negative predictive value
Fig 2. Image of dermal thickness measure
Table I. Demographics of participants in the validation
study
Group No.
Gender
Age, median
(IQR), yM F
Post-DVT (without ulceration) 20 15 5 69 (64-76)
Venous ulcer 20 12 8 72 (56-78)
Healthy controls 31 13 18 65 (50-74)
DVT, Deep vein thrombosis; F, female; IQR, interquartile range; M, male.
Fig 3. Bars show the comparison of dermal thickness between the
three groups in the validation study (Mann-Whitney U-test). IQ,
Interquartile; PTS, post-thrombotic syndrome.of 90.3% (95% CI, 80.4%-95.7%).DISCUSSION
Two differentHFU scanners were used to enable a high
throughput of patients, and analysis confirmed that the
type of scanner was not a significant source of variation in
this study. In practice, a range of suitable scanners could be
used, and all would require further validation and the
development of standard operating procedures before use
in monitoring and diagnostic testing.
The validation study confirmed that dermal thickness
measurements obtained by HFU imaging are potentially
useful for discriminating between individuals with different
severities of venous disease. The range of normal values was
narrow, and the venous ulcer group before compression
therapy showed consistently high dermal thickness. The
dermal thickness in the patients in the PTS group without a
history of ulceration was between these two extremes.
The standard method of treatment for healing ulcers
and preventing ulcer recurrence is compression therapy.
obtained using the DermaScan-C scanner.
Fig 4. Effect of compression therapy on dermal thickness in patients
with venous leg ulceration. IQ, Interquartile;Normal,Median dermal
thickness of healthy controls in the validation study.With the compression system used in the study, applied by
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HFU imaging reduced to normal levels during the first 5
weeks of treatment. The median dermal thickness increased
by a small amount at week 7 in this study, but this difference
was not significant.
Because the principle of compression therapy is to
reduce edema, HFU imaging provides the opportunity to
make direct measurements of the effectiveness of this mech-
anism. In clinical practice it is very difficult to establish in
the short-term whether the level of compression is appro-
priate for a given patient, whether the compression has
been adequately applied, and whether it is having any
benefit. We propose that serial measurements of dermal
thickness by HFU imaging can be used to monitor the
effectiveness of compression therapy and allow adjustments
in the level of compression to be made throughout the
entire course of treatment. Serial measurements of dermal
thickness during compression treatment would require ac-
cess to a portable HFU device in the clinic.
Further studies are required to demonstrate (1) the
effect of monitoring dermal thickness during the course of
compression therapy on ulcer healing rates, and hence, (2)
Table II. CEAP classification profile and demographics of
CEAP category Clinical features
C0 No visible or palpable venous disease
C1 Telangiectasias
C2 Varicose veins
C3 Edema
C4a Hyperpigmentation, eczema
C4b Lipodermatosclerosis
C5 Healed leg ulcers
C6 Active (open) leg ulcers
Total
F, Female; IQR, interquartile range; M, male.
Fig 5. Dermal thickness of subjects classified according to the clin-
ical component of theCEAP classification. IQ, Interquartile;Normal,
dermal thickness of healthy controls in the validation study.cost-effectiveness. HFU imaging may also be a useful toolto assess other venous interventions, for example, perfora-
tor surgery.
Previous studies have indicated that skin changes and
chronic venous ulceration will develop in a proportion of
patients after DVT. The incidence of ulceration after a
DVT in previous studies has been evaluated at between 5%
and 10% of patients.16 A Cochrane systematic review con-
cluded that compression stockings reduce the occurrence
of symptoms of PTS, including leg ulceration, by 50%.17
The most recent edition of the “American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines
(8th Edition)” now recommends compression stockings
alongside conventional anticoagulation (grade 1A recom-
mendation) in all patients with acute symptomatic proximal
DVT for the prevention of PTS, where feasible.18 Early
identification of skin changes in patients after DVT will
assist the identification of patients for whom compression
therapy may prevent the development of severe PTS.
Most PTS symptoms have been shown to occur 2
years of DVT.19 The inclusion of patients with a DVT at
3 years previously in this study ensured that symptoms
had reached the highest level of CEAP categorization at the
time of the analysis. Our results demonstrate an increase in
dermal thickness with increasing CEAP category and con-
firm that edema is quantitatively more severe in the higher
CEAP categories. Dermal thickness was also significantly
higher in the C2 category (varicose veins) than in healthy
controls, one level lower than the C3 level of clinically
detectable edema. The information gained from a test
based on a 1.985 mm cutoff for severe PTS (positive
predictive value of 46.9%) would be a powerful incentive
for the application of graduated compression stockings. No
means are currently available to predict the 5% to 10% of
individuals who will present with severe PTS after DVT.20
According to these data, 53.1% of patients identified by the
test would not go on to develop severe post-thrombotic
changes of lipodermatosclerosis or ulceration. A propor-
tion of patients, however, would still be likely to benefit
from wearing compression stockings with the reduction of
other signs and symptoms of PTS, such as pain, edema,
hyperpigmentation, and venous eczema. In post-DVT pa-
icipants in the CEAP classification study
No. (%)
Gender
Age
Median (IQR) yM F
9 (5.7) 3 6 61 (56-61)
10 (6.4) 5 5 54 (38.5-68.5)
5 (3.2) 1 4 71 (60-71)
29 (18.5) 9 20 65 (60-73)
41 (26.1) 18 23 69 (61-76)
13 (8.3) 12 1 68 (61-74)
27 (17.2) 16 11 69 (57.5-78)
23 (14.6) 17 6 62 (49.5-70.5)
157 (100) 81 76parttients a once-off scan could be performed using a suitable
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DVT (to be defined in a prospective study), and the cost of
this scan would be small compared with the savings from
reduced incidence of leg ulceration and other symptoms of
PTS.
Some of the symptomatic individuals in the CEAP
classification study were bandaged or were wearing com-
pression stockings at the time of the study. Because com-
pression reduces dermal thickness, this will have reduced
the ability of the dermal thickness measurements to dis-
criminate between adjacent CEAP categories. We argue
that the positive and negative predictive values of a test
based on a cutoff value of dermal thickness would be
improved if this variable had been controlled. Also, the
study does not show at what time after a DVT the increases
in dermal thickness are predictive of the development of
serious skin changes. Prospective studies will be required to
determine the dynamics of dermal thickness changes after
DVT, the relationship to the development of PTS, and
accurate cutoff values for clinical application.
CONCLUSION
Dermal thickness measured by HFU imaging is a sen-
sitive and quantitative method for evaluating dermal edema
in patients with venous disease and enables the monitoring
of edema reduction by compression therapy in the treat-
ment of chronic venous leg ulcers. A prospective study is
required to determine the temporal dynamics of dermal
thickness changes after DVT and the relationship to the
development of PTS. This noninvasive and objective test
has the potential to be beneficial in the follow-up of pa-
tients after a DVT and could provide good clinical evidence
for using graduated elastic compression stockings to con-
trol edema and prevent the development of more advanced
skin changes.
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